Key result
Traditional and emerging biomarkers significantly improve the early diagnosis, risk stratification, and treatment monitoring of cardiogenic shock.
Why the study?
Cardiogenic shock is among the most fatal cardiovascular critical conditions, and biomarker research combining traditional and emerging markers has advanced early diagnosis, risk stratification, and treatment monitoring.
Systematic Review
Traditional and emerging biomarkers hold significant value in the early diagnosis, risk stratification, and treatment monitoring of cardiogenic shock.
Answers are grounded in this paper and cite their sources.
Supports combined biomarker panels in CS protocols now; extends evidence for their diagnostic and prognostic integration.
Cardiogenic shock (CS) is one of the most fatal syndromes among cardiovascular critical conditions. With the advancement of biomarker research, the combination of traditional and emerging biomarkers has significantly improved the early diagnosis, risk stratification, and treatment monitoring of CS. This article provides a systematic review of biomarkers that hold significant value in current clinical practice and explores their pathophysiological mechanisms and clinical application prospects.
No takes yet. Share an insight, caveat, or question.
QIN et al. (2025) conducted a systematic review in Cardiogenic shock. Biomarkers was evaluated. Traditional and emerging biomarkers significantly improve the early diagnosis, risk stratification, and treatment monitoring of cardiogenic shock.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: